193 results
8-K
EX-1.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
of the Registration Statement and the Prospectus present fairly, in all materials respects, the information set forth therein on a basis consistent … , contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture
DEFA14A
TPST
Tempest Therapeutics Inc
23 Apr 24
Additional proxy soliciting materials
4:04pm
Additional Materials
Soliciting Material under § 240.14a-12
TEMPEST THERAPEUTICS, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s … with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
Your Vote Counts! TEMPEST
DEFA14A
pbvx 73sz3w03j
1 May 23
Additional proxy soliciting materials
4:11pm
8-K
EX-10.1
2ytxcmpl
21 Jun 22
Departure of Directors or Certain Officers
7:31am
DEFA14A
zzyx9 jkdt49ha
26 May 22
Additional proxy soliciting materials
4:06pm
D
jne4030vq5i45
11 May 22
$15M in equity / options / securities to be acquired, sold $15M, 2 investors
3:42pm